EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMMDG00005012144
Gene Symbol: BRAF
1 Cross references
219 Possible Orthologues:

B1 Bradykinin Receptor-Like

Ensembl ID : ENSMMDG00005014718
Gene Symbol: LOC115354504
3 Cross references
147 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSMMDG00005014722
Gene Symbol: LOC115354433
2 Cross references
146 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSMMDG00005007904
Gene Symbol: BCL2L1
3 Cross references
221 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMMDG00005016634
Gene Symbol: BCR
1 Cross references
205 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSMMDG00005006246
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSMMDG00005003394
Gene Symbol: LOC115374956
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMMDG00005017409
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSMMDG00005013985
Gene Symbol: CXCR2
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMMDG00005016278
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSMMDG00005024000
Gene Symbol: LOC115378235
2 Cross references
359 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMMDG00005004817
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).